Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-80
SponsorFujian Medical University
About this trial
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.
Eligibility criteria
Qualifiers
Age ≥ 14 years at enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC).
LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board.
Disqualifiers
Patients who refuse tumor tissue biopsy or surgery.
Prior thyroid or major neck surgery.
History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan.
Concurrent active malignancies.
Trial design
Treatments tested in this trial
- Multitarget Tyrosine Kinase Inhibitors
- BRAF inhibitor dabrafenib and MEK inhibitor trametinib
- RET Inhibitor
- PD(L)-1 inhibitor
- Biopsy
- Surgery
- Surgery
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fujian Medical University
Lead sponsor
Fujian Medical University Union Hospital
Sponsor institution
Source ClinicalTrials.gov